cyc 682 has been researched along with thalidomide in 1 studies
Studies (cyc 682) | Trials (cyc 682) | Recent Studies (post-2010) (cyc 682) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
---|---|---|---|---|---|
30 | 5 | 18 | 9,789 | 1,385 | 4,342 |
Protein | Taxonomy | cyc 682 (IC50) | thalidomide (IC50) |
---|---|---|---|
Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
Protein cereblon | Homo sapiens (human) | 1.38 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baer, MR; Gojo, I | 1 |
1 other study(ies) available for cyc 682 and thalidomide
Article | Year |
---|---|
Novel agents for the treatment of acute myeloid leukemia in the older patient.
Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide | 2011 |